EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy

Rosalyne Laura Westley, Katie Biscombe, Alex Dunlop, Adam Mitchell, Uwe Oelfke, Simeon Nill, Julia Murray, Angela Pathmanathan, Shaista Hafeez, Chris Parker, Ragu Ratnakumaran, Sophie Alexander und 3 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2023.09.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Rosalyne Laura Westley und 14 weiteren Autor:innen. Beteiligte Einrichtung: Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom. Electronic address: rosalyne.westle…. Hauptthemen laut MEDLINE: Gastrointestinal Diseases, Prostatic Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Ultrahypofractionated radiation therapy (UHRT) is an effective treatment for localized prostate cancer with an acceptable toxicity profile; boosting the visible intraprostatic tumor has been shown to improve biochemical disease-free survival with no significant effect on genitourinary (GU) and gastrointestinal (GI) toxicity. METHODS AND MATERIALS: HERMES is a single-center noncomparative randomized phase 2 trial in men with intermediate or lower high risk prostate cancer. Patients were allocated (1:1) to 36.25 Gy in 5 fractions over 2 weeks or 24 Gy in 2 fractions over 8 days with an integrated boost to the magnetic resonance imaging (MRI) visible tumor of 27 Gy in 2 fractions. A minimization algorithm with a random element with risk group as a balancing factor was used for participant randomization. Treatment was delivered on the Unity MR-Linac (Elekta AB) with daily online adaption. The primary endpoint was acute GU Common Terminology Criteria for Adverse Events version 5.0 toxicity with the aim of excluding a doubling of the rate of acute grade 2+ GU toxicity seen in PACE. Analysis was by treatment received and included all participants who received at least 1 fraction of study treatment. This interim analysis was prespecified (stage 1 of a 2-stage Simon design) for when 10 participants in each treatment group had completed the acute toxicity monitoring period (12 weeks after radiation therapy). RESULTS: Acute grade 2 GU toxicity was reported in 1 (10%) patient in the 5-fraction group and 2 (20%) patients in the 2-fraction group. No grade 3+ GU toxicities were reported. CONCLUSIONS: At this interim analysis, the rate of GU toxicity in the 2-fraction and 5-fraction treatment groups was found to be below the prespecified threshold (5/10 grade 2+) and continuation of the study to complete recruitment of 23 participants per group was recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal DiseasesProstatic NeoplasmsHumansMaleMagnetic Resonance ImagingPelvisProstateUrogenital SystemRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Autor:innen und Institutionen

  • Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom. Electronic address: rosalyne.westley@rmh.nhs.uk.
  • Institute of Cancer Research, London, United Kingdom.
  • Joint Department of Physics, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United Kingdom.
  • Royal Marsden NHS Foundation Trust, London, United Kingdom.

Förderung

  • Cancer Research UK

Zitieren

APA

Westley, R. L., Biscombe, K., Dunlop, A., Mitchell, A., Oelfke, U., Nill, S., Murray, J., Pathmanathan, A., Hafeez, S., Parker, C., Ratnakumaran, R., Alexander, S., Herbert, T., Hall, E., & Tree, A. C. (2024). Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.09.032

Vancouver

Westley RL, Biscombe K, Dunlop A, Mitchell A, Oelfke U, Nill S, et al. Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2023.09.032

BibTeX
@article{Westley2024,
  author = {Westley, Rosalyne Laura and Biscombe, Katie and Dunlop, Alex and Mitchell, Adam and Oelfke, Uwe and Nill, Simeon and Murray, Julia and Pathmanathan, Angela and Hafeez, Shaista and Parker, Chris and Ratnakumaran, Ragu and Alexander, Sophie and Herbert, Trina and Hall, Emma and Tree, Alison C},
  title = {Interim Toxicity Analysis From the Randomized HERMES Trial of 2- and 5-Fraction Magnetic Resonance Imaging–Guided Adaptive Prostate Radiation Therapy},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2023.09.032}
}
Kostenlos starten →